Our Speakers

Stefania Alvino

Daiichi Sankyo

Omnichannel Marketing Manager & Digital Orchestrator (HAT) - Specialty Division

How Digital Health can improve patient quality of life?

  • Cronic disease & technology
  • Digital health and digital solutions
  • From the virtual hospital to the health smart home
Stefania Alvino Photo Daiichi Sankyo Logo

Geoff Rollason


Patient Experience & Service Director Oncology

Pfizer's position re patient centricity

  • Our legacy work in collaborating with the NHS to improve the experience of cancer patients
  • Our progress in engaging patients over the period
  • The insights we are gathering as a consequence of gathering insights from people with lived experience of cancer
  • The work going on to bring those insights to bear on our strategy and business direction of travel
Geoff Rollason Photo pfizer Logo

Maarten Boomsma


Clinical Research Director

Impact of pandemics and military conflicts on the world of clinical research & patient retention

  • What has been the impact of COVID-19 on clinical trials?
  • What is the impact of Ukraine-Russia military conflict on clinical trials?
  • How patient centricity can help to cope with exceptional emergency situations?
Maarten Boomsma Photo Sanofi Logo

Dr. Jose Manuel Cervera Grau

Eli Lilly

Executive Director Clinical Oncology

The impact of AI on the clinical trial process

  • Modeling the PROs in functional synthetic control arms (external arms)
  • How an External Control Arm does it works?
  • Horn Clauses in AI for clinical trials
  • NELL in Industry
Dr. Jose Manuel Cervera Grau Photo Eli Lilly Logo

Jost Leemhuis


Safety Science Partner

Understanding Patients' real Needs during Drug Development-the Patient Safety perspective

  • Pharma Drug Development
  • Clinical Trials
  • Patient Centricity
  • Patient Involvement
Jost Leemhuis Photo Roche Logo
Patient recruitment, enrollment, and retention are significant elements of clinical trial programs. Recruiting and retaining the ideal patients at the right time is critical for producing an accurate database for scientific and regulatory purposes. If not, it can cause the development timetable to be extended by many years. To optimise both, you must have a strategy and successfully employ analytics and technology while keeping the participant's user experience in mind. The demands of patient groups, the relevance of diversity, the application of digital technology, the challenges of consent protocols, direct-to-patient models, and many other attributes must all be considered.